BRUIN CLL-321: Randomized phase III trial of pirtobrutinib versus idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma Meeting Abstract
| Authors: | Sharman, J. P.; Munir, T.; Grosicki, S.; Roeker, L.; Burke, J. M.; Chen, C. I.; Grzasko, N.; Follows, G.; Mátrai, Z.; Sanna, A.; Yi, S.; Feng, R.; Hua, V. M.; Holodja, J.; Jurczak, W.; Ritgen, M.; Qiu, L. G.; Bosch, F.; Coombs, C. C.; Bao, K.; Patel, V.; Liu, B.; Compte, L.; Guntur, A.; Wang, Y.; Hill, M.; Leow, C. C.; Ghia, P.; Barr, P. M. |
| Abstract Title: | BRUIN CLL-321: Randomized phase III trial of pirtobrutinib versus idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 886 |
| Language: | English |
| ACCESSION: | WOS:001412804100030 |
| DOI: | 10.1182/blood-2024-198147 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
